JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Camptodactyly: classification and results of nonoperative treatment.

To assess the relationship between clinical presentation and response to treatment, we reviewed the management of 59 involved proximal interphalangeal (PIP) joints in 22 patients with camptodactyly at a mean follow-up of 33 months. This population represented 24 cases of isolated infantile camptodactyly (type I), five cases of adolescent camptodactyly (type II), and 30 cases of syndromic camptodactyly (type III). Treatment response was assessed through passive range of motion measurements. Splinting and close adherence to an occupational therapy program were particularly effective for type I digits. We also recommend this approach for type II and type III camptodactyly, although severe deformities and well-established contractures are more common in these patients. We reserve operative intervention for only those patients who fail nonoperative management.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app